Certara, Inc. (NASDAQ:CERT) Shares Bought by Ameriprise Financial Inc.

Ameriprise Financial Inc. grew its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 864.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,779,655 shares of the company's stock after purchasing an additional 3,387,590 shares during the period. Ameriprise Financial Inc. owned 2.35% of Certara worth $40,253,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Venturi Wealth Management LLC boosted its stake in shares of Certara by 839.1% during the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after purchasing an additional 2,509 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Certara by 48.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock worth $34,000 after acquiring an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. acquired a new stake in shares of Certara in the fourth quarter worth approximately $47,000. Blue Trust Inc. boosted its position in shares of Certara by 20.9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd boosted its position in shares of Certara by 204.7% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after acquiring an additional 3,656 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on CERT shares. Barclays raised shares of Certara from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $11.00 to $14.00 in a research report on Thursday. Stephens reissued an "overweight" rating and issued a $17.00 target price on shares of Certara in a research report on Thursday, February 27th. Robert W. Baird raised their target price on shares of Certara from $9.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. KeyCorp raised their target price on shares of Certara from $15.00 to $18.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 16th. Finally, JMP Securities reissued a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $15.67.

Certara Trading Up 0.9%

Shares of CERT stock opened at $11.98 on Monday. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -59.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $17.76. The firm's 50 day moving average price is $11.67 and its two-hundred day moving average price is $11.69.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million for the quarter, compared to analysts' expectations of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. Certara's revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 earnings per share. On average, analysts anticipate that Certara, Inc. will post 0.28 EPS for the current year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.